Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Milestone Pharmaceuticals Inc

Healthcare US MIST

1.23USD
-0.06(4.65%)

Last update at 2026-06-05T20:15:00Z

Day Range

1.211.28
LowHigh

52 Week Range

1.334.10
LowHigh

Fundamentals

  • Previous Close 1.29
  • Market Cap87.88M
  • Volume2410861
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-61.00600M
  • Revenue TTM1.00M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 5.00M
  • Diluted EPS TTM-1.21

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -58.38800M -42.85300M -49.98400M -55.28500M -23.11100M
Minority interest - - - - 0.00000M
Net income -57.13400M -42.63300M -49.96700M -55.22900M -23.18500M
Selling general administrative 15.72M 12.40M 10.29M 7.00M 3.05M
Selling and marketing expenses 9.10M 7.00M 5.94M 8.89M 3.92M
Gross profit 5.00M 15.00M - - 0.00000M
Reconciled depreciation 0.09M 0.09M 0.10M 0.04M 0.01000M
Ebit -59.73100M -43.07300M -50.71000M -57.88100M -23.82200M
Ebitda -59.64200M -42.98000M -50.61300M -57.84300M -23.81200M
Depreciation and amortization 0.09M 0.09M 0.10M 0.04M 0.01000M
Non operating income net other - 0.22M 0.73M - -
Operating income -59.64200M -43.07300M -50.71000M -57.88100M -23.82200M
Other operating expenses 64.64M 58.07M 50.71M 57.88M 23.82M
Interest expense -1.25400M 0.22M 0.73M 2.60M 0.00000M
Tax provision - 0.00000M -0.01700M -0.05600M 0.07M
Interest income 1.25M 0.22M 0.73M 2.60M 0.71M
Net interest income 1.25M 0.22M 0.73M 2.60M 0.71M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -1.25400M -0.22000M -0.01700M -0.05600M 0.07M
Total revenue 5.00M 15.00M 0.00000M 0.00000M 0.00000M
Total operating expenses 64.64M 58.07M 50.71M 57.88M 23.82M
Cost of revenue - - - - 0.00000M
Total other income expense net 1.25M 0.22M 0.73M 2.60M 0.71M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -58.38800M -42.85300M -49.96700M -55.22900M -23.18500M
Net income applicable to common shares -58.38800M -42.85300M -49.96700M -55.22900M -23.18500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 75.23M 74.48M 119.85M 149.97M 123.43M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.18M 6.34M 4.66M 6.15M 2.42M
Total liab 58.45M 8.13M 7.25M 6.86M 8.51M
Total stockholder equity 16.77M 66.35M 112.60M 143.12M 114.92M
Deferred long term liab - - - - -
Other current liab 2.70M 3.38M 2.17M 1.27M 3.62M
Common stock 260.50M 273.90M 251.90M 251.68M 226.25M
Capital stock 260.50M 273.90M 251.90M 251.68M 226.25M
Retained earnings -326.02600M -266.34100M -206.31900M -163.46600M -113.49900M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 13.76M 7.64M 114.14M 72.31M 119.82M
Cash and equivalents - - - - -
Total current liabilities 7.23M 6.14M 6.78M 6.16M 8.33M
Current deferred revenue - - - - -
Net debt 38.02M -5.14500M -113.44300M -71.36900M -119.30400M
Short term debt 0.55M 0.49M 0.22M 0.24M 0.33M
Short long term debt - - - - -
Short long term debt total 51.77M 2.49M 0.70M 0.94M 0.51M
Other stockholder equity 33.83M 58.79M 68.65M 56.54M 3.81M
Property plant equipment - 2.68M 0.21M 1.29M 0.93M
Total current assets 73.03M 71.80M 118.92M 148.69M 122.50M
Long term investments - - - - -
Net tangible assets - 66.35M 112.60M 143.12M 114.92M
Short term investments 52.24M 56.95M - 70.00M -
Net receivables 3.85M 1.21M 0.48M 0.95M 0.84M
Long term debt 49.77M - - - -
Inventory - -0.33100M -0.35600M -0.72500M -0.57800M
Accounts payable 3.98M 2.26M 4.38M 4.64M 4.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 48.46M - -1.63400M -1.63400M -1.63400M
Additional paid in capital - - - - -
Common stock total equity - - 251.90M 251.68M 226.25M
Preferred stock total equity - - - - -
Retained earnings total equity - - -206.31900M -163.46600M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.71M 0.98M 0.93M
Deferred long term asset charges - - - - -
Non current assets total 2.19M 2.68M 0.93M 1.29M 0.93M
Capital lease obligations 2.00M 2.49M 0.70M 0.94M 0.51M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -57.12400M 70.00M -70.00000M -0.38400M 16.00M
Change to liabilities -0.90700M 0.64M -2.08300M 3.52M 2.88M
Total cashflows from investing activities -57.12400M 70.00M -70.00000M -0.38400M 16.00M
Net borrowings - - - - 0.00000M
Total cash from financing activities 3.09M 5.05M 73.22M 85.41M 80.11M
Change to operating activities -1.60000M 1.52M -3.75900M -0.73500M -1.16100M
Net income -58.38800M -42.85300M -49.96700M -55.22900M -23.18500M
Change in cash -106.50500M 41.83M -47.50800M 33.87M 75.07M
Begin period cash flow 114.14M 72.31M 119.82M 85.95M 10.88M
End period cash flow 7.64M 114.14M 72.31M 119.82M 85.95M
Total cash from operating activities -52.46900M -33.22400M -50.73200M -51.15200M -21.04600M
Issuance of capital stock 2.63M 0.00000M 24.92M 85.36M 80.00M
Depreciation 0.09M 0.09M 0.10M 0.04M 0.01000M
Other cashflows from investing activities - - - 0.03M 16.00M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - 0.10M 0.04M 0.12M -0.27100M
Sale purchase of stock - 0.12M 48.45M 85.41M 80.46M
Other cashflows from financing activities 0.46M 5.05M 48.31M 0.04M 80.11M
Change to netincome - 7.28M 4.67M 0.99M 0.63M
Capital expenditures 0.27M 0.00000M 0.10M 0.41M 0.00500M
Change receivables - 0.10M 0.04M - -
Cash flows other operating - 1.52M -3.75900M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 41.83M -47.50800M - -
Change in working capital -3.26200M 2.26M -5.80700M 2.85M 1.50M
Stock based compensation 9.05M 7.28M 4.95M 1.19M 0.63M
Other non cash items 0.04M 32.64M -34.16200M -27.80600M -56.07200M
Free cash flow -52.74100M -33.22400M -50.73200M -51.56500M -21.05100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MIST
Milestone Pharmaceuticals Inc		 -0.06 4.65% 1.23 - - 91.95 5.48 77.72 -1.3626
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc

1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6

Key Executives

Name Title Year Born
Mr. Joseph G. Oliveto M.B.A. CEO, Pres & Director 1968
Mr. Amit Hasija CFO & Exec. VP of Corp. Devel. 1973
Dr. Philippe Douville M.B.A., Ph.D. Founder, Strategic Advisor & Member of Scientific Advisory Board 1962
Mr. Jeff Nelson Chief Operating Officer NA
Mr. Roshan Girglani VP of Marketing NA
Ms. Kimberly Sheehan VP of HR NA
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. Chief Medical Advisor & Member of the Scientific Advisory Board 1956
Dr. Guy Rousseau SVP of Regulatory Affairs and Quality Management NA
Mr. Lorenz Muller Chief Commercial Officer 1964
Dr. David B. Bharucha FACC, M.D., Ph.D. Chief Medical Officer 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions